Nikaia Pharmaceuticals
Develops small-molecule NIK inhibitors for cancer and autoimmune disease treatment
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About Nikaia Pharmaceuticals
Nikaia Pharmaceuticals is developing selective small-molecule inhibitors of NF-κB-inducing kinase (NIK), a regulator of the non-canonical NF-κB pathway. Its research targets cancer, including melanoma, and autoimmune diseases.
The company was founded in 2024 and is based in Nice, France. It is completing preclinical development of an oncology candidate and expanding its autoimmune disease pipeline.
Product: Small-molecule NIK inhibitors in preclinical development for cancer and autoimmune diseases.
Jobs at Nikaia Pharmaceuticals
Leadership
- Rachid Benhida · FounderSource: company website
- Thierry Passeron · MD, PhD.Source: company website
- Jean-Baptiste Bouin · CEOSource: company website
- Pascal Dao · Head of operationsSource: company website
More biotech & pharma companies
Noraker
Develops and manufactures resorbable biomaterial implants for surgeons treating bone defects and supporting bone regenerationNew on EvolcNordic Pharma
Specialty pharmaceutical company marketing licensed prescription products to doctors and patients in FranceNew on EvolcNorgine
Pharmaceutical products and European commercialization partnerships for patients and healthcare systemsNew on EvolcNovalix
Preclinical drug discovery services for biotechnology and pharmaceutical companiesNew on EvolcNovaptech
Custom aptamer development, assays and biosensors for biotechnology, pharmaceutical, academic and agri-food organizationsNew on EvolcNovo Nordisk
Pharmaceutical company making diabetes, obesity and rare disease medicines and injection pens for patients in FranceNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
